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Neuropeptide growth factors and cancer
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During the past decade, the expression of growth factors and
their receptors in tumours has attracted considerable atten-
tion. Cancer cells are postulated to escape from normal
growth control by altered expression of growth factors, their
receptors or intracellular signals. The discovery that many of
these changes are associated with oncogene expression has
been fundamental to the view that cancers result from the
accumulation of multiple genetic insults. Although the roles
of polypeptide growth factors, such as epidermal growth
factor and platelet-derived growth factor have been widely
discussed, neuropeptides have only recently been recognised
as important mitogens (Hanley, 1985; Zachary et al., 1987).
This review considers the evidence for neuropeptides as
tumour growth factors.
Neuropeptides are small regulatory molecules that are
widely distributed, particularly in the nervous and cardiovas-
cular systems and gut. They can act as neurotransmitters and
hormones. Many neuropeptides exist in multiple molecular
forms, and different neuropeptides are frequently co-localised
in neurones, suggesting complex modulation of their effects.
Because of this, direct evidence of their actions cannot be
obtained in vivo. Determination of the effects of individual
peptides has only been possible since homogeneous cell lines
were developed, such as murine Swiss 3T3 fibroblasts, which
are reversibly growth arrested in serum-free medium.
Vasopressin was the first neuropeptide unequivocally
shown to act as a growth factor (Rozengurt et al., 1979). The
demonstration that bombesin, which was known to be
secreted by small cell lung cancer (SCLC; Moody et al., 1981;
Wood et al., 1981; Erisman et al., 1982) was also mitogenic
(Rozengurt & Sinnett-Smith, 1983) focussed interest on
neuropeptides as possible mediators of cancer growth.
Because the bombesin-like peptides, including gastrin-
releasing peptide (GRP), are the best characterised of the
neuropeptide growth factors, their actions will be considered
in detail. Evidence for other neuropeptides as growth factors,
and their possible roles in malignant cells, will then be dis-
cussed.
Bombesin/GRP
GRP (27 amino acids) is the principal mammalian homo-
logue of the amphibian peptide bombesin (14 amino acids). It
is found in neurones of the gut and central nervous system,
and is sparsely present in neuroendocrine cells of the adult
lung. Vagal stimulation causes GRP release from the pan-
creas, and this stimulates the secretion of a variety of hor-
mones including gastrin, leading to gastric acid and amylase
secretion.
Bombesin/GRP is a potent mitogen for Swiss 3T3 cells. It
is active in the absence of other growth factors (with half-
maximal effect at 1 nM) but synergises with insulin (Rozen-
gurt & Sinnett-Smith, 1983). Bombesin/GRP has been
reported to be mitogenic for explants of human bronchial
epithelium at concentrations of 100 nM (Willey et al., 1984).
Because GRP is abundant in fetal lung, it has been suggested
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to act as a developmental growth factor (Wharton et al.,
1978; Spindel et al., 1987). Indirect evidence that bombesin
can act as a growth factor in vivo has been obtained in
rodents, in which chronic bombesin administration leads to
gastric antral cell proliferation and pancreatic hypertrophy
(Lezoche et al., 1981; Lehy et al., 1983; Lhoste et al., 1989).
Bombesin/GRP is found in specimens and cell lines of
SCLC, and also in some bronchogenic adenocarcinomas
(Moody et al., 1981; Wood et al., 1981; Erisman et al., 1982).
The mRNA for GRP has been detected in SCLC and cor-
relates well with immunoreactive GRP (Suzuki et al., 1987).
GRP receptors have been demonstrated on SCLC cells
(Moody et al., 1985a; Layton et al., 1988) and GRP has been
shown to stimulate SCLC growth in vitro and in vivo at
concentrations of 50 nM- 1.8 gLM (Weber et al., 1985; Carney
et al., 1987; Alexander et al., 1988). Thus the components
required for autocrine growth stimulation are present,
although the lack of correlation between amounts of GRP
secreted, response to exogenous GRP and number of binding
sites is disappointing (Carney et al., 1987). The autocrine
hypothesis was tested by Cuttitta et al. (1985) using a mono-
clonal antibody to bombesin. The clonal growth of two
SCLC lines was inhibited in vitro, as was the growth of one
as xenografts in nude mice. Unfortunately, this interesting
report has not been followed by further observations in other
cell lines. Thus GRP appears to act as an autocrine growth
factor, at least in a proportion of SCLC (Kado-Fong &
Malfroy, 1989).
Although interest in GRP as a tumour growth factor has
been concentrated on SCLC, it is detectable in other
neuroendocrine tumours such as carcinoids and medullary
thyroid carcinomas (Spindel et al., 1984; Bostwick & Bensch,
1985). In addition bombesin/GRP has been found to have
effects (although not necessarily of growth promotion) in
hormone-dependent tumours of prostate and breast (Bologna
et al., 1989; Weber et al., 1989; Giacchetti et al., 1990; Patel
& Schrey, 1990). Bombesin has also been implicated in the
devleopment of some carcinogen-induced pancreatic and
hepatocellular tumours in rats (Lhoste & Longnecker, 1987;
Seglen et al., 1989).
Mode of action
Bombesin/GRP was first shown to be mitogenic in Swiss 3T3
cells, and much work elucidating its signal transduction path-
ways has been done in these cells (Rozengurt, 1986). GRP
binds to a single class of high affinity receptors of M,
75,000-85,000 (Zachary & Rozengurt, 1985, 1987; Kris et
al., 1987). These are glycoproteins with a core of Mr 42,000,
which are associated with a guanine nucleotide binding pro-
tein (G-protein; Sinnett-Smith et al., 1990; Coffer et al.,
1990). They have now been shown to be members of the
G-protein coupled receptor super-family, with seven
predicted transmembrane domains (Battey et al., 1991) like
the receptor for substance K (see below).
Binding of bombesin/GRP to its receptor triggers a cas-
cade of signals in the membrane, cytosol and nucleus leading
to DNA synthesis 10-15 h later. One of the earliest changes
is a rapid exchange of Na+, H+ and K+ ions across the cell
membrane, which leads to cytoplasmic alkalinisation and an
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increase in intracellular [K+] (Mendoza et al., 1986).
Bombesin/GRP also stimulates phospholipase C-mediated
hydrolysis of phosphatidyl-4,5-bisphosphate in the plasma
membrane, generating diaclyglycerol and inositol-1,4,5-
trisphosphate, which causes rapid mobilisation of Ca2" from
intracellular stores (Mendoza et al., 1986; Takuwa et al.,
1987). The diacylglycerol thus produced activates protein
kinase C, leading to phosphorylation of its M, 80,000 sub-
strate protein (Rozengurt et al., 1983; Isacke et al., 1986;
Zachary et al., 1986). Bombesin/GRP is a potent mitogen
which is active alone, and demonstrates considerable redun-
dancy in its signalling pathways: accumulation of cAMP and
prostaglandins have recently been demonstrated to be impor-
tant accessory signals (Millar & Rozengurt, 1988, 1990). Like
PDGF and other growth factors, bombesin/GRP rapidly and
transiently induces expression of the oncogenes c-fos and
c-myc (Letterio et al., 1986; Rozengurt & Sinnett-Smith,
1988). As these cellular oncogenes encode nuclear proteins, it
is plausible that their expression plays a part in the transduc-
tion of the mitogenic signal to the nucleus.
Available evidence suggests that the effects of bombesin/
GRP in SCLC resemble those in Swiss 3T3 cells. '25I-GRP
binds to specific cell surface receptors on SCLC cell lines
(Moody et al., 1985a; Layton et al., 1988) and stimulation
with bombesin/GRP causes rapid and transient mobilisation
of intracellular Ca2" (Heikkila et al., 1987; Moody et al.,
1987) with inositol phosphate turnover (Trepel et al., 1988).
The finding that neuropeptide antagonists characterised in
Swiss 3T3 cells can block receptor-mediated events in SCLC
strengthens the predictive value of the fibroblast model (Woll
& Rozengurt, 1990).
Gastrin
This 17 amino acid peptide is localised to neurones of the
hypothalamus and pituitary, and neuroendocrine cells of the
gastric antrum and proximal duodenum. Gastrin release
stimulates gastric acid secretion, gastric motility and contrac-
tion of the lower oesophageal sphincter. The receptors and
signalling pathways remain obscure.
Considerable indirect evidence indicates that gastrin has
trophic effects on the normal pancreas and gastrointestinal
mucosa in vivo. Exogenous gastrin stimulates DNA synthesis
in the fundic gastric mucosa and an increase in pancreatic
weight (Hansen et al., 1976; Solomon et al., 1987; Ryberg et
al., 1990). Surgical antrectomy in the rat leads to reduced
DNA synthesis in the pancreas, oxyntic glands, duodenal and
colonic mucosa that can be reversed with pentagastrin treat-
ment (Dembinski & Johnson, 1979). It also impairs the pro-
liferative response to partial hepatectomy (Rasmussen et al.,
1990).
Persistent elevation of plasma gastrin in rats treated with
H2 antagonists and omeprazole has been associated with the
development of gastric carcinoid tumours (Ekman et al.,
1985; Poynter et al., 1985; Betton et al., 1988). In contrast,
gastrin-secreting tumours in man (gastrinomas) are
associated with peptic ulcers and diarrhoea, but not with
gastric carcinoids. Gastrin has also been implicated in the
pathogenesis of some gastric and colonic adenocarcinomas
(Lamers & Jansen, 1988). Plasma gastrin levels are higher in
patients with colonic polyps or cancer than in control sub-
jects (Smith et al., 1989) but interestingly, the presence of
gastrin receptors on colonic cancers is associated with a good
prognosis (Upp et al., 1989). Gastrin stimulates the growth
of rat gastric cancer cells in vitro (Kobori et al., 1982) and of
gastric and colonic tumour xenografts in nude mice, appar-
ently through specific receptors (Sumiyoshi et al., 1984; Singh
et al., 1986; Watson et al., 1989). Preliminary studies with
gastrin antagonists and antibodies have shown growth re-
tardation of colonic cancer cell lines and suggest that colon
tumours can be stimulated by gastrin in an autocrine fashion
(Hoosein et al., 1988, 1990). Gastrin has also been found in
some bronchogenic tumours (Gazdar & Carney, 1984;
Rehfeld et al., 1989).
Cholecystokinin
Multiple molecular forms of cholecystokinin are found, but
the biological activity resides in the conserved eight carboxy-
terminal amino acids. It is localised to the proximal small
intestine, ileum, cerebral cortex, hypothalamus and brain-
stem. Its main effects in the gut are to stimulate gall bladder
contraction and secretion, but its central actions probably
mediate pain and satiety.
Cholecystokinin has trophic effects on normal pancreas, as
shown by measurements of pancreatic weight and DNA syn-
thesis (Haarstad et al., 1986; Douglas et al., 1989). It can also
directly stimulate the growth of rat gastric cancer cells in
vitro (Kobori et al., 1982) and has been implicated in the
growth of gut tumours (Lamers & Jansen, 1988; Hoosein et
al., 1990). Cholecystokinin has been demonstrated in a liver
metastasis from an islet cell tumour (Madsen et al., 1986),
pituitary tumours (Rehfeld et al., 1987) and some SCLC
(Gazdar & Carney, 1984; Rehfeld et al., 1989). Cholecy-
stokinin receptors have been found in some SCLC (Yoder &
Moody, 1987) and shown to mobilise Ca2+ in SCLC cell lines
(Staley et al., 1989a; Woll & Rozengurt, 1989a; Bunn et al.,
1990), suggesting a possible role as growth factors for a
subset of these tumours.
Neurotensin
This 13 amino acid peptide is found principally in the central
nervous system, pituitary gland and gut. Its functions are
unclear, but intracerebral injection is known to cause
hypotension, hypothermia and hypoglycaemia, in addition to
release of pituitary hormones.
Neurotensin is produced by some SCLC (Wood et al.,
1981; Goedert et al., 1984; Moody et al., 1985b). Ca2+-
mobilising receptors for it have recently been demonstrated
on SCLC cell lines (Staley et al., 1989b; Woll & Rozengurt,
1989a; Bunn et al., 1990). The finding that exogenous
neurotensin can stimulate SCLC growth suggests that it may
act as an autocrine growth factor for this tumour (Davis et
al., 1989).
Vasopressin
Vasopressin (antidiuretic hormone) is a cyclic nonapeptide
which is secreted in the hypothalamus and passes down
neural axons to the posterior pituitary where it is released
into the circulation. Acting as an endocrine hormone, it
stimulates hepatic glycogenolysis and has pressor effects on
arteriolar smooth muscle, mediated by Ca2+-mobilising VI
receptors. It also has antidiuretic effects mediated by
adenylate cyclase-coupled V2 receptors in the kidney. As yet,
the molecular structures of the vasopressin receptors are
unknown.
Direct evidence for the mitogenic effects of vasopressin was
first obtained in Swiss 3T3 cells (Rozengurt et al., 1979). It
acts synergistically with insulin at nanomolar concentrations.
Vasopressin binds to specific, high-affinity VI receptors in
these cells (Collins & Rozengurt, 1983) and elicits an array of
early responses including inositol phosphate production,
Ca2+-mobilisation, cytoplasmic alkalinisation, activation of
protein kinase C and oncogene induction (Rodriguez-Pena &
Rozengurt, 1986; Lopez-Rivas et al., 1987; Rozengurt &
Sinnett-Smith, 1988). In vivo, vasopressin facilitates the pro-
liferative responses to haemorrhage (Hunt et al., 1977;
Feuerstein et at., 1985) and partial hepatectomy (Russell &
Bucher, 1983) in rats. It has also been implicated in the
control of brain development in fetal rats (Boer, 1985).
Vasopressin has not been shown to be mitogenic for
tumours. It is, however secreted (with other neurophysins) by
up to 65% of SCLC (North et al., 1980; Sorenson et al.,
1981; Sausville et al., 1985) and is associated with the syn-
drome of dilutional hyponatraemia found in these patients
(Schwartz et al., 1957). Vasopressin secretion is more com-
NEUROPEPTIDE GROWTH FACTORS AND CANCER 471
mon in patients with extensive than limited disease (Maurer
et al., 1983) and hyponatraemia is an adverse prognostic
indicator (Rawson & Peto, 1990). The recent demonstration
that vasopressin can stimulate Ca2+-mobilisation in SCLC
cell lines (Woll & Rozengurt, 1989a; Bunn et al., 1990)
implies that these cells have vasopressin receptors. This sug-
gests that vasopressin could have an autocrine or paracrine
function in these tumours.
Tachykinins
The tachykinins, including substance P (11 amino acids) and
substance K (ten amino acids), have similar activities but
bind to distinct receptors. They are widely distributed in the
brain, spinal cord and gut neurones. Their release causes
local pain, smooth muscle contraction and vasodilatation, in
addition to their systemic effects of stimulting natriuresis and
salivation, and inhibiting pancreatic and biliary secretion.
The substance K receptor was the first neuropeptide receptor
to be cloned and sequenced (Masu et al., 1987). The sub-
stance P receptor has considerable homology with it (Yokota
et al., 1989; Hershey & Krause, 1990). They are members of
a group of receptors characterised by having seven helical
transmembane domains, clustered to form a ligand-binding
pocket, and coupled to Ca2+-mobilising G-proteins (Dohl-
man et al., 1987; Lefkowitz & Caron, 1988).
Substance P has been shown to have direct mitogenic
effects on T-lymphocytes, mediated by specific receptors, at
concentrations as low as 100 pM (Payan et al., 1983).
Tachykinins can also stimulate growth of human skin fibro-
blasts, arterial smooth muscle cells and keratinocytes (Nils-
son et al., 1985; Tanaka et al., 1988). These, and earlier
observations in vivo, have led to speculation that tachykinins
mediate inflammation and wound healing (Payan, 1989).
Substance P receptors are expressed in healing glia following
neuronal injury (Mantyh et al., 1989). Tachykinins have also
been implicated in the pathogenesis of rheumatoid arthritis,
as substance P stimulates prostaglandin E2 release and pro-
liferation of synoviocytes (Lotz et al., 1987).
Tachykinins are not known to be tumour growth factors,
but they are secreted by some carcinoid tumours (Norheim et
al., 1986; Bishop et al., 1989). The tachykinins have been
demonstrated to mobilise Ca2+ in SCLC cell lines, but not to
stimulate growth (Takuwa et al., 1990). An amphibian
tachykinin, physalaemin (11 amino acids), is produced by
some SCLC and appears to be able to inhibit SCLC growth,
suggesting a possible regulatory role in this cancer (Lazarus
et al., 1983; Bepler et al., 1987).
Bradykinin
The nonapeptide bradykinin is generated in the plasma or
tissues from high molecular weight precursors (kininogens)
by the action of kallikreins, which are activated during
proteolysis and clotting. It is rapidly degraded, so plasma
concentrations are very low. Bradykinin is implicated in
smooth muscle contraction, vasodilatation and vascular
permeability. It is one of the most potent pain producing
substances known, and its receptors are localised to the
nocioceptive sensory pathways (Steranka et al., 1988).
Bradykinin is a weak mitogen for human fibroblasts (Owen
& Villereal, 1983; Coughlin et al., 1985) but a potent mitogen
for Swiss 3T3 cells (Woll & Rozengurt, 1988a). Acting syner-
gistically with insulin in these cells, nanomolar concentrations
of bradykinin achieve a response equivalent to that obtained
with serum. Although bradykinin receptor subtypes can be
distinguished pharmacologically, these do not correlate with
functional differences, and the structures of the receptors are
unknown. Bradykinin induces monovalent ion fluxes, tran-
sient protein kinase C activation, inositol phosphate produc-
tion, Ca2+-mobilisation, prostaglandin E2 production and
myc induction (Owen & Villereal, 1983; Coughlin et al., 1985;
Jackson et al., 1987; Issandou & Rozengurt, 1990).
Bradykinin has not been demonstrated to act as a tumour
growth factor. Its production however, has long been
associated with the flushing caused by carcinoid tumours,
which can secrete large quantities of vasoactive peptides
(Oates et al., 1964; Gustafsen et al., 1987). Interestingly,
[hydroxyprolyl3]-bradykinin has been detected in the ascitic
fluid of a patient with gastric cancer (Maeda et al., 1988).
Bradykinin has now been shown to stimulate Ca2"
mobilisation in SCLC cell lines (Woll & Rozengurt, 1989a;
1990). Becuase it is produced at sites of tissue damage and
rapidly inactivated, it could have local effects within tumours
without being detected in serum by current assay methods.
Opioids
Endogenous opioid peptides including the enkephalins,
endorphins and dynorphins are widely distributed in the
central nervous system. Multiple subtypes of receptors have
been identified using a variety of agonists and antagonists.
Because of their central role in pain transmission, opiate
pharmacology has been studied in detail.
P-endorphin stimulates lymphocyte proliferation in vitro,
although this effect may not be mediated directly by opiate
receptors as it is not blocked by the opiate antagonist nal-
trexone (Gilman et al., 1982). Dynorphins and enkephalins
appear to be involved with vasopressin in the proliferative
response of the rat marrow to haemorrhage (Feuerstein et
al., 1985). Further, P-endorphin has been implicated in the
ability of newts to regenerate amputated limbs (Morley &
Ensor, 1986).
SCLC cell lines contain opioid peptides and receptors
(Roth & Barchas, 1985). Opioids have been reported both to
inhibit and to stimulate SCLC growth (Davis et al., 1989;
Maneckjee & Minna, 1990). Opioids are also reported to
inhibit the growth of breast cancer cells (Maneckjee et al.,
1990). Conversely, neuroblastoma xenograft growth can be
inhibited by naltrexone (Zagon & McLaughlin, 1987), a
reminder of the complex interactions between multifunctional
growth factors (Sporn & Roberts, 1988)
Vasoactive intestinal peptide (VIP)
This 28 amino acid peptide is found in large amounts in
mammalian brain, and in gut mucosa and muscle, where it is
localised to postganglionic nerves. It is also found in the
salivary glands, pancreas, respiratory and urogenital tracts.
Neural stimulation causes release of VIP, which binds to
specific receptors. These receptors also bind related hormones
(e.g. secretin, glucagon) with lower affinity. VIP induces
relaxation of smooth muscle, vasodilatation and enhanced
small intestinal and colonic secretion.
In Swiss 3T3 cells, VIP stimulates mitogenesis in the
presence of insulin and cAMP phosphodiesterase inhibitors.
In contrast to bombesin, vasopressin and bradykinin, VIP is
a weak mitogen for these cells, and its effects are mediated by
elevation of cAMP without CA2+-mobilistion or protein
kinase C activation (Zurier et al., 1988). VIP also stimulates
adenylate cyclase activity and cell proliferation in
keratinocytes (Haegerstrand et al., 1989).
VIP has been found in pancreatic, neural and cervical
tumours and phaeochromocytomas (Bunnett et al., 1984;
Inoue et al., 1984; Viale et al., 1985), but is not known to be
a growth factor for them. Pancreatic and intestinal VIP-
secreting tumours (vipomas) present with the Verner-
Morrison syndrome of watery diarrhoea, hypokalaemia and
achlorhydria. Interestingly, this syndrome, and elevated
serum VIP levels, were recently reported in a patient with
SCLC (Noseda et al., 1989). Some SCLC appear to have
binding sites for VIP and VIP can stimulate growth of
certain SCLC cell lines in vitro. This effect could be mediated
by bombesin because exogeneous VIP stimulates bombesin/
GRP secretion (Bepler et al., 1988).
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Further neuropeptide growth factors
The number of neuropeptides shown to be mitogenic is
rapidly increasing. Serotonin (5-hydroxy tryptamine) has
long been known to be a component of the carcinoid flush
and is also secreted by some SCLC (Horai et al., 1973;
Maton, 1988). Its receptor has been cloned and belongs to
the class of G-protein linked receptors with seven helical
transmembrane domains (Julius et al., 1988). Expression of
the serotonin receptor in fibroblasts leads to malignant trans-
formation, suggesting that it can act as a proto-oncogene
(Julius et al., 1989). Whether this is significant in any human
cancer is unknown. The angiotensin receptor, which has a
similar structure, is also encoded by an oncogene, mas
(Young et al., 1986; Jackson et al., 1988).
The recently described neuropeptide endothelin, and
related vasoconstrictor peptides, stimulate DNA synthesis by
a Ca2" dependent pathway in a variety of cell types including
fibroblasts, smooth muscle and glial cells (Komuro et al.,
1988; Yanigasawa et al., 1988; Takuwa et al., 1989; Fabregat
& Rozengurt, 1990). Endothelin is produced by breast, pan-
creas and colon cancer cell lines, but it is not yet known
whether these, or surrounding stromal cells, are stimulated by
it (Kusuhara et al., 1990).
Therapeutic implications
The recognition that many neuropeptides can act as growth
factors, the identification of these peptides and their recep-
tors in human cancers, and the discovery that some are
encoded by oncogenes (Young et al., 1986; Jackson et al.,
1988; Julius et al., 1989), have led to speculation that
neuropeptides are important regulators of tumur growth. It
has long been known that tumours can secrete diverse pep-
tides, in a heterogeneous fashion. Only recently however have
multiple receptors been demonstrated on cancer cells,
prompting the suggestion that growth of these tumours is
regulated by multiple factors acting in a paracrine or auto-
crine manner (Woll & Rozengurt, 1989a).
SCLC is the best example of this model. It can secrete a
wide variety of ectopic peptides and hormones (Table I).
Many of these have been shown to act as growth factors for
other cell types, in vitro and in vivo. The demonstration of
receptors for bombesin/GRP, bradykinin, cholecystokinin,
galanin, gastrin, neurotensin, tachykinins and vasopressin on
SCLC permits speculation that these diverse peptides may
contribute to multiple growth loops. Direct evidence of
growth stimulation in SCLC is at present available only for
Table I Peptides and hormones secreted by SCLC
Adrenocorticotrophin Lipotropin
Atrial natriuretic peptide Neurotensin
Bombesin/GRP Opioid peptides
Calcitonin Oxytocin




Follicle stimulating hormone Somatostatin
Gastrin Substance K
Glucagon Substance P
Granulocyte colony stimulating factor Transferrin
Growth hormone Vasopressin
Growth hormone releasing factor VIP
Insulin-like growth factor-I
bombesin/GRP, neurotensin and P-endorphin, but it is likely
that further neuropeptide mitogens will soon be added to this
list. Other tumuors for which neuropeptide growth factors
may be important include the neuroendocrine cancers (e.g.
carcinoids, medullary carcinoma of thyroid) and adenocar-
cinomas of stomach, colon, breast and prostate.
The model proposed, of tumour growth regulation by
multiple neuropeptide growth factors, has implications for
future therapeutic strategies. Attempts to produce highly
specific antibodies and antagonists to these growth factors
are unlikely to be successful except in a minority of cases. At
best, 30-60% of cells may express receptors for any individ-
ual peptide (Bunn et al., 1990) but all or most tumours will
express receptors for multiple peptides (Woll & Rozengurt,
1989a). Possible strategies to exploit this knowledge include
targetting a signalling process common to the diverse pep-
tides, attacking an enzyme essential to growth factor produc-
tion, and developing broad-spectrum receptor antagonists.
Elucidation of mitogenic signalling pathways has identified a
number of intracellular messengers used by many mitogens,
such as protein kinase C activation or ion fluxes, that could
be targets for novel therapies (Woll & Rozengurt, 1989b).
Broad-spectrum neuropeptide antagonists, that appear to act
on a class of G-protein-linked, Ca2+-mobilising receptors,
have already been shown to block the early events stimulated
by diverse neuropeptides and to inhibit SCLC growth in vitro
(Woll & Rozengurt, 1988b, 1990). Increasing knowledge of
the actions of neuropeptide growth factors in tumours will
undoubtedly lead to innovations in cancer treatment.
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